See the DrugPatentWatch profile for sarclisa

Sarclisa, also known as isatuximab, is an antibody therapy used to treat multiple myeloma, a type of blood cancer. It is an IgG kappa monoclonal antibody that targets the CD38 protein, which is highly expressed on the surface of multiple myeloma cells.

Sarclisa was genetically engineered using recombinant DNA technology. This process involves the manipulation of DNA sequences to create a desired protein, in this case, an antibody that can specifically bind to the CD38 protein.

The first step in the engineering of Sarclisa involved the identification and isolation of the gene that codes for the variable region of the antibody that recognizes the CD38 protein. This gene was then cloned and inserted into a vector, which is a small, self-replicating piece of DNA that can be introduced into a host cell.

The vector containing the CD38-targeting antibody gene was then introduced into a host cell, which was chosen for its ability to efficiently produce and secrete the antibody. The host cell used for the production of Sarclisa is a Chinese hamster ovary (CHO) cell line.

Once the host cell has taken up the vector and begun producing the antibody, it undergoes a series of purification steps to isolate the Sarclisa protein from the other cellular components.

It's important to note that the exact methods used to engineer Sarclisa are proprietary and are not publicly disclosed by the drug's manufacturer, Sanofi. However, the general process of antibody engineering using recombinant DNA technology is well-established and widely used in the biopharmaceutical industry.

In summary, Sarclisa is a monoclonal antibody that targets the CD38 protein and is used to treat multiple myeloma. It was genetically engineered using recombinant DNA technology, which involves the manipulation of DNA sequences to create a desired protein, in this case, an antibody that can specifically bind to the CD38 protein.

Sources:

* [Sarclisa Prescribing Information](https://www.sarclisa.com/-/media/sarclisa/pdfs/sarclisa-prescribing-information.pdf)
* [Antibody Engineering and Therapeutics](https://www.cambridge.org/core/books/antibody-engineering-and-therapeutics/B9780128127152)
* [Recombinant DNA Technology](https://www.nature.com/scitable/topicpage/recombinant-dna-technology-14089/)
* [Chinese Hamster Ovary Cells](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789095/)
* [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/sarclisa)